Sung Yun Cho
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Sung Yun Cho has a total of 80 co-authors. Here are the top co-authors by number of shared publications:
Jong Yeon Hwang
Therapeutic and Biotechnology Division Korea Research Institute of Chemical Technology 141 Gajeong‐ro, Yuseong‐gu, Daejeon 34114 Republic of Korea
7 shared publicationsHeejung Jung
Drug Discovery Division Korea Research Institute of Chemical Technology Daejeon 305‐606 South Korea
5 shared publications- Jae Du Ha
Drug Discovery Division, Korea Research Institute of Chemical Technology, PO Box 107, Daejeon 305-600, Republic of Korea
5 shared publications Joo‐Youn Lee
Therapeutics and Biotechnology Division Korea Research Institute of Chemical Technology Yuseong‐Gu Daejeon Republic of Korea
5 shared publicationsChi Hoon Park
Therapeutics and Biotechnology Division Korea Research Institute of Chemical Technology Yuseong‐Gu Daejeon Republic of Korea
4 shared publications- Chi Hoon Park
Bio & Drug Discovery Division, Korea Research Institute of Chemical Technology, Daejeon, Republic of Korea
4 shared publications
Latest Publications
- Open Access
- 2 February 2022
- Published by Wiley in Bulletin of the Korean Chemical Society
- Vol. 43 (4) , 577-584
Pyrazolo[3,4‐d]pyrimidine derivatives as irreversible Bruton's tyrosine kinase inhibitors
4,6‐Disubstituted pyrazolo[3,4‐d]pyrimidine derivatives were explored as irreversible Bruton's tyrosine kinase (BTK) inhibitors. The structure–activity relationship was established with over 20 derivatives synthesized to determine initial hit compounds, based on activities against BTK enzyme and TMD8 cells. It turned out that introducing 1‐acrylamido‐4‐aminopiperdine (1b) at the C4 position of pyrazolopyrimidine as in 5e, and 3‐acrylamido‐aniline (1j) as 4‐position substituent, such as in 9d, 10d, and 10e, delivered potent in vitro enzyme activities as well as TMD8 cell‐based cytotoxicities. Considering kinase selectivity profiles, 5e was selected for in vivo efficacy studies with a murine xenograft model using TMD8 cells, where 5e exhibited moderate tumor growth inhibition activities. Further optimization of 5e and 9d may lead to clinically useful compounds to overcome B‐cell‐mediated hematologic cancers.
- 2 February 2022
- Published by Wiley in Bulletin of the Korean Chemical Society
- Vol. 43 (4) , 577-584
Open AccessPyrazolo[3,4‐d]pyrimidine derivatives as irreversible Bruton's tyrosine kinase inhibitors
4,6‐Disubstituted pyrazolo[3,4‐d]pyrimidine derivatives were explored as irreversible Bruton's tyrosine kinase (BTK) inhibitors. The structure–activity relationship was established with over 20 derivatives synthesized to determine initial hit compounds, based on activities against BTK enzyme and TMD8 cells. It turned out that introducing 1‐acrylamido‐4‐aminopiperdine (1b) at the C4 position of pyrazolopyrimidine as in 5e, and 3‐acrylamido‐aniline (1j) as 4‐position substituent, such as in 9d, 10d, and 10e, delivered potent in vitro enzyme activities as well as TMD8 cell‐based cytotoxicities. Considering kinase selectivity profiles, 5e was selected for in vivo efficacy studies with a murine xenograft model using TMD8 cells, where 5e exhibited moderate tumor growth inhibition activities. Further optimization of 5e and 9d may lead to clinically useful compounds to overcome B‐cell‐mediated hematologic cancers.
- 13 December 2020
- Published by Wiley in Bulletin of the Korean Chemical Society
- Vol. 42 (2) , 206-211
Design and Synthesis of 5‐Aryl‐substituted Phenylpyrimidine‐2,4‐diamine Derivatives as Novel Mer and Tyro3 Kinase Inhibitors
5‐Aryl‐substituted (piperdin‐4‐yl)pyrimidine‐2,4‐diamine derivatives were synthesized and their inhibitory activities were evaluated against TAM kinase (Tyro3, Axl, Mer), respectively. Detailed SAR studies on the fifth position of pyrimidine could lead to the discovery of potent and selective TAM kinase inhibitor. Compounds 6f, 7b, and 7f exhibited potent inhibitory activity and excellent selectivity toward Axl, Tyro3 and Mer kinases. Molecular docking studies corroborated that slight changes of substituents induced dramatic structural change of Met596, 623, 674 backbone carbonyl and amide in the hinge region of Axl, Tyro3, Mer, and resulted in different binding poses of 6f, 7b, and 7f, respectively. It was identified as a strong possibility to control selectivity by structural modification of phenyl substituents of pyrimidine as a new class of TAM kinase inhibitors.
- 13 December 2020
- Published by Wiley in Bulletin of the Korean Chemical Society
- Vol. 42 (2) , 206-211
Design and Synthesis of 5‐Aryl‐substituted Phenylpyrimidine‐2,4‐diamine Derivatives as Novel Mer and Tyro3 Kinase Inhibitors
5‐Aryl‐substituted (piperdin‐4‐yl)pyrimidine‐2,4‐diamine derivatives were synthesized and their inhibitory activities were evaluated against TAM kinase (Tyro3, Axl, Mer), respectively. Detailed SAR studies on the fifth position of pyrimidine could lead to the discovery of potent and selective TAM kinase inhibitor. Compounds 6f, 7b, and 7f exhibited potent inhibitory activity and excellent selectivity toward Axl, Tyro3 and Mer kinases. Molecular docking studies corroborated that slight changes of substituents induced dramatic structural change of Met596, 623, 674 backbone carbonyl and amide in the hinge region of Axl, Tyro3, Mer, and resulted in different binding poses of 6f, 7b, and 7f, respectively. It was identified as a strong possibility to control selectivity by structural modification of phenyl substituents of pyrimidine as a new class of TAM kinase inhibitors.
- Open Access
Therapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer
The receptor tyrosine kinase c-MET regulates processes essential for tissue remodeling and mammalian development. The dysregulation of c-MET signaling plays a role in tumorigenesis. The aberrant activation of c-MET, such as that caused by gene amplification or mutations, is associated with many cancers. c-MET is therefore an attractive therapeutic target, and inhibitors are being tested in clinical trials. However, inappropriate patient selection criteria, such as low amplification or expression level cut-off values, have led to the failure of clinical trials. To include patients who respond to MET inhibitors, the selection criteria must include MET oncogenic addiction. Here, the efficacy of ABN401, a MET inhibitor, was investigated using histopathologic and genetic analyses in MET-addicted cancer cell lines and xenograft models. ABN401 was highly selective for 571 kinases, and it inhibited c-MET activity and its downstream signaling pathway. We performed pharmacokinetic profiling of ABN401 and defined the dose and treatment duration of ABN401 required to inhibit c-MET phosphorylation in xenograft models. The results show that the efficacy of ABN401 is associated with MET status and they highlight the importance of determining the cut-off values. The results suggest that clinical trials need to establish the characteristics of each sample and their correlations with the efficacy of MET inhibitors.
Open AccessTherapeutic Efficacy of ABN401, a Highly Potent and Selective MET Inhibitor, Based on Diagnostic Biomarker Test in MET-Addicted Cancer
The receptor tyrosine kinase c-MET regulates processes essential for tissue remodeling and mammalian development. The dysregulation of c-MET signaling plays a role in tumorigenesis. The aberrant activation of c-MET, such as that caused by gene amplification or mutations, is associated with many cancers. c-MET is therefore an attractive therapeutic target, and inhibitors are being tested in clinical trials. However, inappropriate patient selection criteria, such as low amplification or expression level cut-off values, have led to the failure of clinical trials. To include patients who respond to MET inhibitors, the selection criteria must include MET oncogenic addiction. Here, the efficacy of ABN401, a MET inhibitor, was investigated using histopathologic and genetic analyses in MET-addicted cancer cell lines and xenograft models. ABN401 was highly selective for 571 kinases, and it inhibited c-MET activity and its downstream signaling pathway. We performed pharmacokinetic profiling of ABN401 and defined the dose and treatment duration of ABN401 required to inhibit c-MET phosphorylation in xenograft models. The results show that the efficacy of ABN401 is associated with MET status and they highlight the importance of determining the cut-off values. The results suggest that clinical trials need to establish the characteristics of each sample and their correlations with the efficacy of MET inhibitors.
- 24 July 2018
- Published by Wiley in Bulletin of the Korean Chemical Society
- Vol. 39 (9) , 1101-1104
Design and Synthesis of Novel 2,4‐Diamino‐5‐pyrazol‐4‐yl Pyrimidine Derivatives as Selective Tyro3 Kinase Inhibitors
- 24 July 2018
- Published by Wiley in Bulletin of the Korean Chemical Society
- Vol. 39 (9) , 1101-1104
Design and Synthesis of Novel 2,4‐Diamino‐5‐pyrazol‐4‐yl Pyrimidine Derivatives as Selective Tyro3 Kinase Inhibitors
- 10 June 2018
- Published by Wiley in Bulletin of the Korean Chemical Society
- Vol. 39 (7) , 853-857
Design and Synthesis of Novel 3‐(2‐Aminopyridin‐3‐yl)‐1,2,4‐Triazolo[4,3‐b]Pyridazine Derivatives as a Reversible Bruton's Tyrosine Kinase Inhibitors
Bruton's tyrosine kinase, a non‐receptor TEC family kinase, plays key role in B cell differentiation, proliferation, and survival. B cell receptor regulates the B cell's fate and cytokine release of B‐lineage lymphoid leukemia cells which are deeply related with the pathogenesis of B‐cell lineage of lymphoma and leukemia and autoimmune diseases. Thus, BTK protein regulation emerged as a promising therapeutic target for both various cancers and autoimmune diseases. Herein, we report the discovery of aminopyridin‐1,2,4‐triazolopyridazine derivatives as a reversible BTK inhibitor, and in vitro enzyme assay and cell based assay result were reported.
- 10 June 2018
- Published by Wiley in Bulletin of the Korean Chemical Society
- Vol. 39 (7) , 853-857
Design and Synthesis of Novel 3‐(2‐Aminopyridin‐3‐yl)‐1,2,4‐Triazolo[4,3‐b]Pyridazine Derivatives as a Reversible Bruton's Tyrosine Kinase Inhibitors
Bruton's tyrosine kinase, a non‐receptor TEC family kinase, plays key role in B cell differentiation, proliferation, and survival. B cell receptor regulates the B cell's fate and cytokine release of B‐lineage lymphoid leukemia cells which are deeply related with the pathogenesis of B‐cell lineage of lymphoma and leukemia and autoimmune diseases. Thus, BTK protein regulation emerged as a promising therapeutic target for both various cancers and autoimmune diseases. Herein, we report the discovery of aminopyridin‐1,2,4‐triazolopyridazine derivatives as a reversible BTK inhibitor, and in vitro enzyme assay and cell based assay result were reported.
- 25 January 2017
- Published by Wiley in Bulletin of the Korean Chemical Society
- Vol. 38 (2) , 278-281
Design and Synthesis of Novel Pyrazolo[3,4‐d]pyrimidin‐1‐yl piperidine Derivatives as Bruton's Tyrosine Kinase Inhibitors
- 25 January 2017
- Published by Wiley in Bulletin of the Korean Chemical Society
- Vol. 38 (2) , 278-281
Design and Synthesis of Novel Pyrazolo[3,4‐d]pyrimidin‐1‐yl piperidine Derivatives as Bruton's Tyrosine Kinase Inhibitors
- Open Access
- 22 January 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-9
Novel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells
C-Met signaling has been implicated in oncogenesis especially in cells with c-met gene amplification. Since 20 % of gastric cancer patients show high level of c-Met expression, c-Met has been identified as a good candidate for targeted therapy in gastric cancer. Herein, we report our newly synthesized c-Met inhibitor by showing its efficacy both in vitro and in vivo. Compounds with both triazolopyrazine and pyridoxazine scaffolds were synthesized and tested using HTRF c-Met kinase assay. We performed cytotoxic assay, cellular phosphorylation assay, and cell cycle assay to investigate the cellular inhibitory mechanism of our compounds. We also conducted mouse xenograft assay to see efficacy in vivo. KRC-00509 and KRC-00715 were selected as excellent c-Met inhibitors through biochemical assay, and exhibited to be exclusively selective to c-Met by kinase panel assay. Cytotoxic assays using 18 gastric cancer cell lines showed our c-Met inhibitors suppressed specifically the growth of c-Met overexpressed cell lines, not that of c-Met low expressed cell lines, by inducing G1/S arrest. In c-met amplified cell lines, c-Met inhibitors reduced the downstream signals including Akt and Erk as well as c-Met activity. In vivo Hs746T xenograft assay showed KRC-00715 reduced the tumor size significantly. Our in vitro and in vivo data suggest KRC-00715 is a potent and highly selective c-Met inhibitor which may have therapeutic potential in gastric tumor with c-Met overexpression.
- 22 January 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-9
Open AccessNovel c-Met inhibitor suppresses the growth of c-Met-addicted gastric cancer cells
C-Met signaling has been implicated in oncogenesis especially in cells with c-met gene amplification. Since 20 % of gastric cancer patients show high level of c-Met expression, c-Met has been identified as a good candidate for targeted therapy in gastric cancer. Herein, we report our newly synthesized c-Met inhibitor by showing its efficacy both in vitro and in vivo. Compounds with both triazolopyrazine and pyridoxazine scaffolds were synthesized and tested using HTRF c-Met kinase assay. We performed cytotoxic assay, cellular phosphorylation assay, and cell cycle assay to investigate the cellular inhibitory mechanism of our compounds. We also conducted mouse xenograft assay to see efficacy in vivo. KRC-00509 and KRC-00715 were selected as excellent c-Met inhibitors through biochemical assay, and exhibited to be exclusively selective to c-Met by kinase panel assay. Cytotoxic assays using 18 gastric cancer cell lines showed our c-Met inhibitors suppressed specifically the growth of c-Met overexpressed cell lines, not that of c-Met low expressed cell lines, by inducing G1/S arrest. In c-met amplified cell lines, c-Met inhibitors reduced the downstream signals including Akt and Erk as well as c-Met activity. In vivo Hs746T xenograft assay showed KRC-00715 reduced the tumor size significantly. Our in vitro and in vivo data suggest KRC-00715 is a potent and highly selective c-Met inhibitor which may have therapeutic potential in gastric tumor with c-Met overexpression.
- 11 January 2016
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 39 (4) , 453-464
Discovery of substituted pyrazol-4-yl pyridazinone derivatives as novel c-Met kinase inhibitors
A series of pyridazin-3-one substituted with morpholino-pyrimidine derivatives was synthesized and evaluated as tyrosine kinase inhibitors against c-Met enzyme, and anti-proliferative activities of Hs746T human gastric cancer cell line. Most of compounds exhibited good biological activity, while compound 10, 12a, 14a displayed excellent c-Met enzyme inhibitory activities and Hs746T cell-based activities.
- 11 January 2016
- Published by Springer Nature in Archives of Pharmacal Research
- Vol. 39 (4) , 453-464
Discovery of substituted pyrazol-4-yl pyridazinone derivatives as novel c-Met kinase inhibitors
A series of pyridazin-3-one substituted with morpholino-pyrimidine derivatives was synthesized and evaluated as tyrosine kinase inhibitors against c-Met enzyme, and anti-proliferative activities of Hs746T human gastric cancer cell line. Most of compounds exhibited good biological activity, while compound 10, 12a, 14a displayed excellent c-Met enzyme inhibitory activities and Hs746T cell-based activities.
- 1 August 2015
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 464 (3) , 762-767
Development of potent ALK inhibitor and its molecular inhibitory mechanism against NSCLC harboring EML4-ALK proteins
- 1 August 2015
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 464 (3) , 762-767
Development of potent ALK inhibitor and its molecular inhibitory mechanism against NSCLC harboring EML4-ALK proteins